It was recently shown that selumetinib, like trametinib, a MEK inhibitor also identified in this study, can stimulate natural killer cells, reduce ACE2 expression in human cells, and reduce cytokine expression in COVID-19 patient plasma, suggesting that this class of drugs may both suppress infection by SARS-CoV-2 and support the body’s immune response to infection39. The gene discussed is MAP2K7; the disease is COVID-19.